Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis

Author

Year

Country

Case

Disease stage

Method

Treatment

Detection

Provided information on cutoff value

Response

Grim[12]

2012

Czech Republic

61

locally advanced

NCT

TAC

IHC

≥10% stained cell

Pathological CR

Chen[13]

2012

China

91

II-IIIC

NCT

PCb

IHC

≥10% stained cell

Pathological CR

Petrarca[14]

2011

Brazil

45

II-III

NCT

AC-T

IHC

>5(expression score range, 0–15)

Pathological CR

von Minckwitz[15]

2008

Germany

196

T2-3(≥3 cm) N0-2 M0

NCT

ddAT with or without tamoxifen

IHC

>1 + (range 0-3+)

Pathological CR

Vargas-Roig[16]

2008

Argentina

110

T2–4 N0–1 M0

NCT

FAC/FEC or D/E

IHC

>33% of stained cells

PR + CR

Keam[17]

2007

Korea,

145

II-III

NCT

docetaxel + doxorubicin

IHC

≥10% stained cell

OR

Tiezzi[18]

2006

Brazil

44

locally advanced

NCT

FEC or DE

IHC

≥5(range 0–7)

OR

Noguchi[19]

2006

Japan

63

NR

NR

Docetaxel

IHC

NR

OR

Mieog[20]

2006

Netherlands

107

T1-4

NCT

FEC

IHC

staining ≥3 indicates positive status

Pathological CR + OR

Fernandez-Sanchez[21]

2006

Mexico

40

IIB-IIIB

NCT

FAC

IHC

≥10% stained cell

OR

Prisack[22]

2005

Germany

517

locally advanced

NCT

EC ± RT

IHC

score ≥100

Pathological CR

Kim[23]

2005

Japan

63

tumor >3 cm and axillary lymph node involvement

NCT

docetaxel

IHC

Grades 2 and 3

Pathologic responders

Buchholz[24]

2005

USA

82

II-IV

NCT

FAC

IHC

presence of any cytoplasmic staining of the tumor cell cytoplasm

Pathological CR

Pusztai[25]

2004

USA

28

IIA-IIIB

NCT

FAC

IHC

any signal in neoplastic cells

Pathological CR

Ogston[26]

2004

UK

104

large and locally advanced

NCT

anthracycline-based ± docetaxel

IHC

≥10% stained cell

Good pathological response

Mathieu[27]

2004

France

129

T2 > 3 cm–T4

NCT

AVCMF or FAC/FEC

IHC

≥10% stained cell

Pathological CR

Stearns[28]

2003

USA

29

T3 or T4

NCT

A-T

IHC

Cytoplasmic staining.Intensity and % positive cells.Score ≥6 = positive

Pathological CR

Geisler[29]

2001

Norway

94

T3/T4 and/or N2 tumors

NCT and first-line

EC

IHC

index ≥ 6

PR

Pernick[30]

2000

USA

34

IIB or III

NCT

adriamycin (n = 32), taxol (n = 7), or taxotere (n = 7)

IHC

5% or more tumor cells stained.

CR

Bottini[31]

2000

Italy

157

T2-4 N0-1 M0

NCT

CMF ± tamoxifen or epirubicin

IHC

≥20% stained cell

CR + OR

Nole[32]

1999

Italy

39

T1-T3

NCT

FLN

IHC

>10% stained cell

OR

Colleoni[33]

1999

Italy

73

T2-T3,N0-2

NCT

FLN or AC

IHC

>10% stained cell

OR

Makris[34]

1997

UK

90

T1(N = 23),T2(n = 58),T3/T4(N = 9)

NCT

mitozantrone, methotrexate and tamoxifen

IHC

NR

OR

  1. NCT, neoadjuvant chemotherapy; IHC, immunohistochemistry; A, doxorubicin; E, epirubicin; D, docetaxel; P, paclitaxel; F, 5-fluorouracil; EC, epirubicin and cyclophosphamide; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide; CMF, cyclophosphamide, mitomycin C and 5-fluorouracil; AVCMF, doxorubicin, vincristine, cyclophosphamide, methotrexate and 5-fluorouracil; P-FEC, sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide; FUMI regimen, 5-fluorouracil (1,000 mg/m2 on days 1 and 2) and mitomycin; PCb, paclitaxel + carboplatin; RT radiation therapy; ddAT, dose-dense (bi-weekly) doxorubicin and docetaxel; FLN, 5-fluorouracil + folinic acid + vinorelbine; D and MF docetaxel; docetaxel to sequential methotrexate and 5-fluorouracil;NR, not reported.